Hansoh and Roche Announce ADC Deal With Over $15 Billion in Milestones

The primary Reuters-sourced content explicitly states that Hansoh units entered a strategic collaboration and licensing agreement with Roche on October 17, 2026, including a $400 million upfront payment, a $110 million first-anniversary payment, eligibility for more than $15 billion in milestones, and tiered royalties. This is a material, forward-looking commercial agreement involving preclinical antibody-drug-conjugate programs, although the contingent economics, early development stage, and undisclosed targets limit certainty about ultimate value and reduce the score relative to an approved or commercial-stage asset. The exact clock time was not provided, so the occurrence timestamp is normalized to midnight UTC on the explicitly stated date. The transaction is distinct from the earlier Roche–Hansoh HS-20110 agreement referenced in the context and warrants a new commercial-agreement event. Only the direct counterparties, Hansoh and Roche, are approved stakeholders; CDMOs and competing oncology companies are excluded because the context provides no product-specific relationship and their effects are speculative.